sugemalimab
cstone pharmaceuticals
['lymsm', 'sugemalimab', 'lymphoma']
congress #asco22 | huiqiang huang presents the data from gemstone-201 evaluating an anti-pd-l1 mab sugemalimab in r/r enktl. n=80 orr was 46.2%; 29 pts achieved cr; 12-mo dor rate was 86%. the 1- &amp; 2-year os rates were 68.6% and 54.6%, respectively #lymphoma #lymsm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm